|
|
Volumn 68, Issue 1, 2011, Pages 6-
|
|
Eribulin approved for advanced breast cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
ERIBULIN;
TAXANE DERIVATIVE;
2 (3 AMINO 2 HYDROXYPROPYL)HEXACOSAHYDRO 3 METHOXY 26 METHYL 20,27 BIS(METHYLENE)11,15 18,21 24,28 TRIEPOXY 7,9 ETHANO 12,15 METHANO 9H,15H FURO(3,2 I)FURO(2',3' 5,6)PYRANO(4,3 B)(1,4)DIOXACYCLOPENTACOSIN 5 (4H) ONE;
2-(3-AMINO-2-HYDROXYPROPYL)HEXACOSAHYDRO-3-METHOXY-26-METHYL-20,27-BIS(METHYLENE)11,15-18,21-24,28-TRIEPOXY-7,9-ETHANO-12,15-METHANO-9H,15H-FURO(3,2-I)FURO(2',3'-5,6)PYRANO(4,3-B)(1,4)DIOXACYCLOPENTACOSIN-5-(4H)-ONE;
ANTINEOPLASTIC AGENT;
FURAN DERIVATIVE;
KETONE;
ADVANCED CANCER;
ALOPECIA;
ANEMIA;
BLOOD CELL COUNT;
BREAST CANCER;
CONSTIPATION;
DRUG APPROVAL;
DRUG INDICATION;
DRUG LABELING;
DRUG SAFETY;
DRUG STORAGE;
FATIGUE;
FEBRILE NEUTROPENIA;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
NAUSEA;
NEUTROPENIA;
NOTE;
PATIENT ASSESSMENT;
PERIPHERAL NEUROPATHY;
PRIORITY JOURNAL;
QT INTERVAL;
RECOMMENDED DRUG DOSE;
SURVIVAL TIME;
WEAKNESS;
BREAST TUMOR;
FEMALE;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
DRUG APPROVAL;
FEMALE;
FURANS;
HUMANS;
KETONES;
UNITED STATES;
|
|
EID: 79953003198
PISSN: 10792082
EISSN: 15352900
Source Type: Journal
DOI: 10.2146/news100085 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
